玻璃体内抗血管内皮生长因子治疗点状内层脉络膜病变继发的脉络膜新生血管。
Intravitreal anti-VEGF treatment for choroidal neovascularization secondary to punctate inner choroidopathy.
作者信息
Barth T, Zeman F, Helbig H, Gamulescu M-A
机构信息
Department of Ophthalmology, University Medical Centre Regensburg, Franz-Josef-Strauß-Allee 11, 93053, Regensburg, Germany.
Centre for Clinical Studies (ZKS), University Medical Centre Regensburg, Franz-Josef-Strauß-Allee 11, 93053, Regensburg, Germany.
出版信息
Int Ophthalmol. 2018 Jun;38(3):923-931. doi: 10.1007/s10792-017-0536-0. Epub 2017 Apr 19.
PURPOSE
To assess the outcome of patients with choroidal neovascularization (CNV) secondary to punctate inner choroidopathy (PIC) receiving intravitreal anti-VEGF (vascular endothelial growth factor) injections.
METHODS
Sixteen eyes of 16 patients diagnosed with CNV secondary to PIC were retrospectively assessed.
RESULTS
Eleven women and five men with a mean age of 35 years (SD 11, range 16-56 years) received intravitreal anti-VEGF for PIC-related CNV. On average, 3.5 injections (SD 2.7, range 1-9) were given per eye. Thirteen eyes were treated with bevacizumab, two eyes with ranibizumab and one eye received both substances. The mean follow-up was 15 months (SD 11, range 6-40 months). BCVA improved in eight eyes (mean Δ +2.8 lines), remained stable in four eyes and decreased in four eyes (mean Δ -4.3 lines).
CONCLUSIONS
CNV development is a frequent complication of PIC. Intravitreal anti-VEGF therapy seems to be safe and effective for PIC-related CNV.
目的
评估继发于点状内层脉络膜病变（PIC）的脉络膜新生血管（CNV）患者接受玻璃体内抗血管内皮生长因子（VEGF）注射的治疗效果。
方法
回顾性评估16例诊断为继发于PIC的CNV患者的16只眼。
结果
11名女性和5名男性，平均年龄35岁（标准差11，范围16 - 56岁），接受玻璃体内抗VEGF治疗PIC相关的CNV。每只眼平均注射3.5次（标准差2.7，范围1 - 9次）。13只眼接受贝伐单抗治疗，2只眼接受雷珠单抗治疗，1只眼同时接受两种药物治疗。平均随访15个月（标准差11，范围6 - 40个月）。8只眼的最佳矫正视力（BCVA）提高（平均提高2.8行），4只眼保持稳定，4只眼下降（平均下降4.3行）。
结论
CNV的发生是PIC常见的并发症。玻璃体内抗VEGF治疗对于PIC相关的CNV似乎是安全有效的。
Zotero 插件